Chronic inflammatory demyelinating polyneuropathy
CIDP · Neurology · 3 drugs · 1 indications
Autoimmune peripheral neuropathy.
Competitive Landscape (3 drugs)
| Drug | Company | Mechanism | Modality | Route | Stage |
|---|
| Claseprubart | — | Selective classical complement C1s inhibitor | Monoclonal antibody | SC | PHASE3 |
| Riliprubart | — | Selective classical complement C1s inhibitor | Monoclonal antibody | SC | PHASE3 |
| Vyvgart | ARGX | FcRn Inhibitor | Antibody | IV / SC | APPROVED |
Indications (1)
Chronic inflammatory demyelinating polyneuropathy (CIDP)
Upcoming Catalysts
Vyvgart - Ocular MG - Ph3 - Topline (ADAPT-OCULUS)CLINICAL
ARGXQ1 2026
Claseprubart - gMG - Ph3 - Trial InitiationCLINICAL
DNTH2026
Vyvgart - oMG - Ph3 - Topline (ADAPT-OCULUS)CLINICAL
ARGX1Q26
Claseprubart - CIDP - Ph3 - Interim Responder Analysis (CAPTIVATE Part A, n=40)CLINICAL
DNTHQ2 2026
Vyvgart - Myositis - Ph2/3 - Topline (ALKIVIA)CLINICAL
ARGXQ3 2026
Claseprubart - MMN - Ph2 - Topline Data (MoMeNtum)CLINICAL
DNTHH2 2026
Vyvgart - ITP - Ph3 - Topline (ADVANCE-NEXT)CLINICAL
ARGXQ4 2026
Vyvgart - AChR- gMG (Seronegative) - FDA Approval DecisionREGULATORY
ARGXBy end of 2026
Riliprubart - CIDP (Refractory) - Ph3 - Primary Data (MOBILIZE)CLINICAL
SNYMay 2027 (primary completion)
Vyvgart - Sjogren's Disease - Ph3 - ToplineCLINICAL
ARGXH2 2027
Data from Supabase · Updated 2026-03-24